Cynvec Product Pipeline

Cynvec uses the base sindbis apoptotic vector CYN 101 as a single agent and in combination therapy against cancer cells over-expressing the laminin receptor. CYN 101 is currently in late-stage preclinical testing, and our first Phase I study will commence in early 2010 in the treatment of ovarian tumors.

Follow-on Products

Beyond CYN 101, Cynvec is conducting research to expand the commercial platform of the vector, which is engineered to accept therapeutic payloads. Cynvec is supporting an extensive research effort at NYU to expand the utility of the vector for cancer treatment by inserting “payloads” including:

  • Re-targeting molecules
  • monoclonal antibodies, single-chain antibodies, or peptides
  • Therapeutic genes
  • Interleukins, interferons, enzymes, antigens
  • Diagnostic markers
  • Thymidine kinase
Sindbis Virus